Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; purified talc; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 19.155 mg (equivalent: escitalopram, qty 15 mg) - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; purified talc; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 6.385 mg (equivalent: escitalopram, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; purified talc; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate, quantity: 6.385 mg (equivalent: escitalopram, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

stat rx usa llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 20 mg - escitalopram tablets usp is indicated for the acute and maintenance treatment of major depressive disorder in adults [see clinical studies (14.1) ]. information related to usage of e scitalopram in adolescents is approved for forest laboratories, inc.'s escitalopram oxalate tablets and oral solution. however, due to forest laboratories, inc.'s marketing exclusivity rights, this drug product is not labeled with that adolescent usage information. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram is i

Stati Uniti - Ingliż - NLM (National Library of Medicine)

citron pharma llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg in 5 ml - escitalopram oral solution usp is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram oral solution usp is indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)] . generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) t